Cytek Biosciences (CTKB)

The company’s distinguishing capability is its Full Spectrum Profiling, or FSP, approach. Rather than measuring only narrow bands of emitted light, Cytek’s systems capture a broader fluorescence signature across multiple lasers and detectors. This design allows laboratories to use larger panels of fluorescent markers and separate overlapping signals through spectral unmixing, supporting more detailed experiments from a single sample.

Cytek’s product portfolio includes the Aurora, Northern Lights, and Aurora Evo flow cytometry systems, along with related sample preparation products, reagents, and analysis software. These platforms are designed to offer high sensitivity and resolution while reducing some of the practical limitations associated with conventional flow cytometers, such as constraints on panel size and signal separation.

As a listed company, Cytek operates in the specialized life sciences instrumentation market, selling to academic research centers, pharmaceutical and biotechnology companies, clinical laboratories, and contract research organizations. Its growth prospects are tied to demand for advanced single-cell analysis, adoption of spectral flow cytometry, and continued investment in biomedical research and clinical assay development.